Organometallic Half-Sandwich Iridium Anticancer Complexes

Abstract

Abstract:The low-spin 5d 6

Comparative solution equilibrium studies on pentamethylcyclopentadienyl rhodium complexes of 2,2ʹ-bipyridine and ethylenediamine and their interaction with human serum albumin

“…On the other hand, the formation of the mixed hydroxido complexes [RhCp*(L)(OH)] + is completely suppressed in the presence of 0.2 M chloride ions. pK a value of the en complex is found to be higher than that of the bpy under both studied conditions as it was also found for the analogous IrCp* complexes of these ligands [57]. (Fig.…”

“…However, no comparable H 2 O/Cl -exchange constants for RhCp* complexes are published in the literature to the best of our knowledge, similar findings were found for IrCp* complexes of bpy, en and phen [57], and for some Os and Ru arene complexes as well [49,58]. Fig.…”

“…This can be a possible explanation for the lack of correlation between pK a and IC 50 values. No correlation was found for the aquated IrCp* complexes of 1,10-phenanthroline (phen), bpy and en ligands as well [57]. On the other hand, complexes of bpy, en and pic show fairly poor or no activity against various human cancer cell lines [12,17] [11,12].…”

Contrasting Reactivity and Cancer Cell Cytotoxicity of Isoelectronic Organometallic Iridium(III) Complexes

“…21 We have previously reported that complex 1 undergoes rapid hydrolysis. 5 based on 1 H NMR peak integrals are shown in Table 2. Figure S2 (Table S5).…”

“…5 Here we focus attention on the role of the XY chelating ligand in (concentrations at which 50% of the cell growth is inhibited) all > 100 μM. 5 Also Cp* PTA iridium(III) complexes (PTA = 1, 3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane), 7 and Cp* pyTz iridium(III) complexes (pyTz = 2-(pyridine-2-yl)thiazole), 8 are reported to be inactive against A2780 cells (IC 50 values > 300 μM). Sheldrick et al have shown that activity can be switched on by incorporating a DNA intercalator (N,N-chelating polypyridyl ligand) into some Cp* Ir III complexes.…”